Tiziana Life Net Income From Continuing Ops Over Time
| TLSA Stock | USD 1.44 0.07 4.64% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tiziana Life Performance and Tiziana Life Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tiziana Life. If investors know Tiziana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tiziana Life assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Tiziana Life Sciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Tiziana Life's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Tiziana Life's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Tiziana Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tiziana Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Tiziana Life's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Tiziana Life Sciences and related stocks such as Anebulo Pharmaceuticals, eXoZymes, and Zentalis Pharmaceuticals Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANEB | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (11.7 M) | (11.6 M) | (8.2 M) | (8.5 M) | (9.8 M) | (10.2 M) |
| EXOZ | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.4 M) | (2 M) | (5.9 M) | (5.3 M) | (5 M) |
| ZNTL | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (46.4 M) | (118.5 M) | (164.3 M) | (220.8 M) | (286.4 M) | (165.9 M) | (149.3 M) | (156.7 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (14.2 M) | (21.7 M) | (19.5 M) | (18.6 M) |
| OKYO | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (1.2 M) | (3 M) | (5.4 M) | (13.3 M) | (16.8 M) | (4.7 M) | (4.2 M) | (4.4 M) |
| ESLA | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (733.7 K) | (1.7 M) | (6.9 M) | (7.3 M) | (7.3 M) | (6.6 M) | (6.9 M) |
| COYA | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (12.2 M) | (12.4 M) | (14.9 M) | (13.4 M) | (14.1 M) |
| PLRX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (631 K) | (41.5 M) | (97.3 M) | (123.3 M) | (155.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| WHWK | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (110.1 M) | (60.5 M) | (65.8 M) | (63.7 M) | (57.3 M) | (60.2 M) |
| MGNX | (260.8 K) | (260.8 K) | (260.8 K) | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (129.7 M) | (202.1 M) | (119.8 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
Tiziana Life Sciences and related stocks such as Anebulo Pharmaceuticals, eXoZymes, and Zentalis Pharmaceuticals Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Tiziana Life Sciences | TLSA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1415 Conduit Street, |
| Exchange | NASDAQ Exchange |
USD 1.44
Check out Tiziana Life Performance and Tiziana Life Correlation. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Tiziana Life technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.